Toxicogenomic predictive modeling: Emerging opportunities for more efficient drug discovery and development

Technological Forecasting and Social Change

Volumn 75, Issue 7, 2008, Pages 905-932

  Amir Aslani, Arsia ^a  

^a Université de Paris 1 Panthéon Sorbonne ^*  (France)

Author keywords

Biotechnology; Drug Discovery; Predictive modeling; R D productivity; Technology Integration; Technology Roadmapping; Toxicogenomics

Indexed keywords

ARSENIC COMPOUNDS; CHEMOTHERAPY; CHLORINE COMPOUNDS; DECISION MAKING; DRUG DOSAGE; DRUG PRODUCTS; HEALTH; HEALTH RISKS; INDICATORS (CHEMICAL); POPULATION STATISTICS; PROBLEM SOLVING; REFRIGERATORS; SAFETY FACTOR; TOXICITY;

ADVERSE DRUG REACTIONS; BIOTECHNOLOGY; CELL FUNCTIONS; CHEMICAL-; CLINICAL DEVELOPMENT; DRUG DISCOVERIES; DRUG DISCOVERY; DRUG DISCOVERY PROCESSES; ECONOMIC IMPACTS; FINANCIAL IMPACTS; HUMAN HEALTH; LONG-TERM SAFETY; PHARMACEUTICAL COMPANIES; PREDICTIVE MODELING; RISK ANALYSES; TECHNOLOGY INTEGRATION; TECHNOLOGY ROADMAPPING; TOXICOGENOMICS;

DRUG DELIVERY;

BIOTECHNOLOGY; DRUG DEVELOPMENT; PHARMACEUTICAL INDUSTRY; PREDICTION; RESEARCH AND DEVELOPMENT; SAFETY; TECHNOLOGICAL DEVELOPMENT; TECHNOLOGY ADOPTION; TOXICITY;

EID: 49649113918     PISSN: 00401625     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.techfore.2007.10.002     Document Type: Article

References (55)

1. DiMasi J.A., Hansen R.W., and Grabowski H.G. The price of innovation: new estimates of drug development costs. J. Health Econ. 22 (2003) 151-185
2. Dickson M., and Gagnon J.P. Key factors in the rising cost of drug discovery and development. Nat. Rev. Drug Discov. 3 (2004) 417-429
3. Bains W. Failure rates in drug discovery and development: will we ever get any better?. Drug Discov. World Fall (2004) 9-18
4. Impact report Tufts Center for the study of drug development. 7(2005) September/October 2005.
5. Lasser K.E., Allen P.D., Woolhandler S.J., Himmelstein D.U., Wolfe S.M., and Bor D.H. Timing of new black box warnings and withdrawals for prescription medications. JAMA 287 (2002) 2215-2220
6. Lazarou J., Pomernaz B.H., and Corey P.N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279 (1998) 1200-1205
7. Public Citizen, Rx R&D Myths: the Case Against the Drug Industry's R&D "Scare Card" (July 2001)
8. Nissen S.E., and Wolski K. Effect of Rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New Engl. J. Med. 356 (2007) 2457-2471
9. Bumol T.B., and Watanabe A.M. Genetic information, genomic technologies, and the future of drug discovery. JAMA 285 (2001) 551-555
10. Hopkins A.L., and Groom C.R. The druggable genome. Nat. Rev. Drug Discov. 1 (2002) 727-730
11. Knowles J., and Gromo G. Target selection in drug discovery. Nat. Rev. Drug Discov. 2 (2003) 63-69
12. Beattie J., and Ghazal P. Post-genomic technologies - thinking beyond the hype. Drug Discov. Today 8 (2003) 909-910
13. FDA. Innovation & Stagnation Challenge & Opportunity on the Critical Path to New Medical Products (March 2004). http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html
14. Kubinyi H. Drug research: myths, hype and reality. Nat. Rev. Drug Discov. 2 (2003) 665-668
15. Noble D. Will genomics revolutionize pharmaceutical R&D?. Trends Biotechnol. 21 (2003) 333-337
16. Baba Y. Development of novel biomedicine based on genome science. Eur. J. of Pharm. Sci. 13 (2001) 3-4
17. Shillingford C.A., and Vose C.W. Effective decision-making: progressing compounds through clinical development. Drug Discov. Today 6 (2001) 941-946
18. Li A.P. Screening for human ADME/Tox drug properties in drug discovery. Drug Discov. Today 6 (2001) 357-366
19. Nassar A.-E.F., Kamel A.M., and Clairmont C. Improving the decision-making process in structural modification of drug candidates: reducing toxicity. Drug Discov. Today 9 (2004) 1055-1064
20. Oberemm A., Onyon L., and Gundert-Remy U. How can toxicogenomics inform risk assessment. Toxicol. Appl. Pharm. 207 (2005) S592-S598
21. Bunin B.A. Increasing the efficiency of small-molecule drug discovery. Drug Discov. Today 8 (2003) 823-826
22. Neumann N.F., and Galvez F. DNA microarrays and toxicogenomics: applications for ecotoxicology. Biotechnol. Adv. 20 (2002) 391-419
23. Whitebread S., Hamon J., Bojanic D., and Urban L. In vitro safety pharmacology profiling: an essential tool for successful drug development. Drug Discov. Today 10 (2005) 1421-1433
24. Bugrim A., Nikolskaya T., and Nikolsky Y. Early prediction of drug metabolism and toxicity: systems biology approach and modeling. Drug Discov. Today 9 (2004) 127-135
25. Bandara L.R., and Kennedy S. Toxicoproteomics - a new preclinical tool. Drug Discov. Today 7 (2002) 411-418
26. Ekins S., Nikolsky Y., and Nikolskaya T. Techniques: application of systems biology to absorption, distribution, metabolism, excretion and toxicity. Trends Pharmacol. Sci. 26 (2006) 202-209
27. Koop R. Combinatorial biomarkers: from early toxicology assays to patient population profiling. Drug Discov. Today 10 (2005) 781-788
28. Fogarty M. The reality of targeted therapies. Scientist 16 (2002) 35
29. McLean L.A., Gathmann I., Capdeville R., Polymeropoulos M.H., and Dressman M. Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with Imatinib. Clin. Cancer Res. 10 (2004) 155-165
30. Claudio J.O., and Stewart A.K. Advances in myeloma genetics and prospects for pharmacogenomic testing in multiple myeloma. Am. J. Pharmacogenomics 5 (2005) 35-43
31. Huang S.-M., and Lesko L.J. Correlation between genes, diseases and biopharmaceuticals. In: Knablein J., and Muller R.H. (Eds). Modern Biopharmaceuticals - Design, Development and Optimization Application of Pharmacogenomics in Clinical Pharmacology - in Volume I: Molecular Medicine (2005), Wiley, VCH
32. Rinne M. Technology roadmaps: infrastructure for innovation. Technol. Forecast. Soc. 71 (2004) 67-80
33. Petrick I.J., and Echols A.E. Technology roadmapping in review: a tool for making sustainable new product development decisions. Technol. Forecast. Soc. 71 (2004) 81-100
34. Phaal R., Farukh C., and Probert D. Customizing roadmapping. Res. Technol. Manag. (2004 March/April) 26-37
35. Subramaniam S. Productivity and attrition: key challenges for biotech and pharma. Drug Discov. Today 8 (2003) 513-515
36. Gassmann O., and Reepmeyer G. Organizing pharmaceutical innovation: from science-based knowledge creators to drug-oriented knowledge brokers. Creat. Innov. Manag. 14 (2005) 233-245
37. Amir-Aslani A., and Negassi S. Is technology integration the solution to biotechnology's low research and development productivity?. Technovation 26 (2006) 573-582
38. Erns E.H., and Di L. Pharmaceutical profiling in drug discovery. Drug Discov. Today 8 (2003) 316-323
39. Lawn R.M., and Lasky L.A. Pharmaceutical biotechnology: the genomes are just the beginning. Curr. Opin. Biotech. 11 (2000) 579
40. Rasmussen K. Creating more effective antidepressants: clues from the clinic. Drug Discov. Today. 11 (2006) 623-631
41. Steiner G., Suter L., Boess F., Gasser R., verade C., Albertini S., and Ruepp S. Discriminating different classes of toxicants by transcript profiling. Environ. Health Perspect. 112 (2004) 1236-1248
42. McMillain M., Nie A., Parker J.B., Leone A., Kemmerer M., Bryant S., Herlich J., Yieh L., Bittner A., Liu X., Wan J., Johnson M.D., and Lord P. Drug-induced oxidative stress in rat liver from a toxicogenomics perspective. Toxicol. Appl. Pharm. 207 (2005) 171-178
43. Caroll P.M., Dougherty B., Ross-Macdonald P., Browman K., and FitzGerald K. Model systems in drug discovery: chemical genetics meets genomics. Pharmacol. Ther. 99 (2003) 183-220
44. Williams D.P., and Kevin Park B. Idiosyncratic toxicity: the role of toxicophores and bioactivation. Drug Discov. Today 8 (2003) 1044-1050
45. Smart A., and martin P. The promise of pharmacogenetics: assessing the prospects for disease and patient stratification. Stud. Hist. Philos. Boil. Biomed. Sci. 37 (2006) 583-601
46. Van Regenmortel M.H.V. Reductionism and complexity in molecular biology. EMBO Rep. 5 (2004) 1016-1020
47. Walker J.D., Carlsen L., Hulzebos E., and Simon-Hettich B. Global government applications of analogues, SARs and QSARs to predict aquatic toxicity, chemical or physical properties, environmental fate parameters and health effects of organic chemicals. SAR QSAR Environ. Res. 13 (2002) 607-616
48. White A.C., Mueller R.A., Gallavan R.H., Aaron S., and Wilson A.G. A multiple in silico program approach for the prediction of mutagenicity from chemical structure. Mutat. Res. 539 (2003) 77-89
49. Simon-Hettich B., Rothfuss A., and Steger-Hartmann T. Use of computer-assisted prediction of toxic effects of chemical substances. Toxicology 224 (2006) 156-162
50. Allen J.F. In silico veritas. EMBO Rep. 2 (2001) 542-544
51. Bogyo M., and Cravatt B.F. Genomics and proteomics: from genes to function: advances in applications of chemical and systems biology. Curr. Opin. Chem. Biol. 11 (2007) 1-3
52. Werner T. Regulatory networks: linking microarray data to systems biology. Mech. Ageing Dev. 128 (2007) 168-172
53. Maggioli J., Hoover A., and Weng L. Toxicogenomic analysis methods for predictive toxicology. J. Pharmacol. Toxicol. 53 (2006) 31-37
54. Cronin M.T.D. Computer-aided prediction of drug toxicity and metabolism. In: Hillisch A., and Hilgenfeld R. (Eds). Modern Methods of Drug Discovery (2003), Birkhauser Verlag, Basel
55. Borzelleca J.F. Paracelsus: herald of modern toxicology. Toxicol. Sci. (2000) 53